Visit
VJHemOnc is excited to present the latest developments in the role of chemotherapy across lymphomas
VJHemOnc is pleased to bring you a feature exploring theĀ emerging applications of MRD in multiple myeloma.
VJHemOnc is pleased to bring you a feature exploring the latest advances and developments in novel agents for MDS, with…
VJHemOnc is pleased to bring you a feature exploring the latest thinking on the application of MRD in AML trials…
The Food and Drug Administration (FDA) granted accelerated approval to pirtobrutinib for the treatment of relapsed/refractory (R/R) mantle cell lymphoma…
Zanubrutinib was approved by the Food and Drug Administration (FDA) on the 19th of January 2023, for the treatment of…
VJHemOnc is thrilled to bring you the latest updates from the 64th American Society of Hematology (ASH) Annual Meeting and…
VJHemOnc is pleased to bring you a feature exploring the latest developments in the treatment of NHL, with leading experts…
VJHemOnc is excited to bring you the latest updates from the 2022 third annual Texas MPN Workshop, which brought together…
On August 24 2022, the European Medicines Agency (EMA) approved the use of teclistamab for the treatment of patients with…
On August 17 2022, the US Food and Drug Administration (FDA) approved the first cell-based gene therapy, betibeglogene autotemcel (beti-cel),…
VJHemOnc is pleased to bring you a feature covering the current state of the field in the treatment CP-CML with…
VJHemOnc is excited to bring you the latest research updates in lymphoid malignancies from the EHA 2022 Congress, which took…
VJHemOnc is excited to bring you the latest research updates in myeloid malignancies from the EHA 2022 Congress, which took…
For decades, autologous stem cell transplants (ASCTs) with high-dose chemotherapy has been the standard of care for patients with newly…
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest hemonc news and updates
Keep up to date with all the latest news with our monthly newsletter